Wall Street brokerages expect Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) to post sales of $5.50 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Tarsus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $10.00 million. Tarsus Pharmaceuticals reported sales of $33.43 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 83.5%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Tarsus Pharmaceuticals will report full-year sales of $30.67 million for the current financial year, with estimates ranging from $30.00 million to $32.00 million. For the next financial year, analysts anticipate that the company will post sales of $11.03 million, with estimates ranging from $3.96 million to $18.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 24.25% and a negative return on equity of 7.66%. The business had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $7.11 million.
In other news, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of the stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $12.67, for a total value of $250,080.46. Following the completion of the sale, the insider now directly owns 2,474,375 shares of the company’s stock, valued at $31,350,331.25. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 33.08% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Citigroup Inc. boosted its position in shares of Tarsus Pharmaceuticals by 123.0% during the fourth quarter. Citigroup Inc. now owns 2,145 shares of the company’s stock worth $48,000 after acquiring an additional 1,183 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Tarsus Pharmaceuticals by 6.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 28,103 shares of the company’s stock worth $632,000 after acquiring an additional 1,623 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Tarsus Pharmaceuticals by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 125,815 shares of the company’s stock worth $2,830,000 after acquiring an additional 2,117 shares during the last quarter. State Street Corp boosted its position in shares of Tarsus Pharmaceuticals by 2.3% during the fourth quarter. State Street Corp now owns 129,742 shares of the company’s stock worth $2,919,000 after acquiring an additional 2,940 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Tarsus Pharmaceuticals by 13.7% during the third quarter. Bank of New York Mellon Corp now owns 24,523 shares of the company’s stock worth $529,000 after acquiring an additional 2,950 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.
Shares of TARS stock opened at $12.05 on Friday. Tarsus Pharmaceuticals has a 12 month low of $11.76 and a 12 month high of $39.08. The stock has a market cap of $249.54 million, a P/E ratio of -16.74 and a beta of 1.45. The company has a 50 day simple moving average of $17.81 and a two-hundred day simple moving average of $21.17.
About Tarsus Pharmaceuticals (Get Rating)
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.